Results 111 to 120 of about 8,174 (197)

Efectividad y seguridad de daclatasvir/ sofosbuvir con o sin ribavirina en pacientes infectados por el genotipo 3 del virus de la hepatitis C: resultados en práctica clínica real [PDF]

, 2019
[Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients.
Castro-Iglesias, Ángeles, Cid-Silva, Purificación, Delgado, Manuel, Margusino-Framiñán, Luis, Martín-Herranz, Isabel, Mena, Álvaro, Pernas, Berta, Pértega-Díaz, Sonia, Rodríguez-Osorio, Iria   +8 more
core   +1 more source

Impact of Sofosbuvir Plus Daclatasvir Therapy on the Frequency of CD200R⁺ Dendritic Cells in Chronic Hepatitis C Virus Infection

Immuno
Dendritic cells (DCs) play a crucial role in controlling viral infections. Little is known about the changes in frequencies of the DC subsets in patients with chronic hepatitis C (CHC), particularly in the era of interferon-free regimens.
Helal F. Hetta, Mohamed A. Mekky, Hani I. Sayed, Ahmed AbdElkader Soliman Mahran, Eman H. Salama, Douaa Sayed, Mariam E. Abdallah, Doaa Safwat Mohamed, Omnia El-Badawy, Mohamed A. El-Mokhtar   +9 more
doaj   +1 more source

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis

Therapeutics and Clinical Risk Management, 2017
Jan Sperl,1 Sona Frankova,1 Miluse Kreidlova,2 Dusan Merta,3 Monika Tothova,4 Julius Spicak1 1Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 2Institute of Medical Biochemistry and Laboratory Medicine, General ...
Sperl J, Frankova S, Kreidlova M, Merta D, Tothova M, Spicak J   +5 more
doaj  

Противовирусные лекарственные средства для лечения гепатита C [PDF]

, 2019
ГЕПАТИТ C /ЛЕК ТЕРПАРЕНТЕРАЛЬНО-ПЕРЕДАВАЕМЫЙ ГЕПАТИТ НИ-A, НИ-B /ЛЕК ТЕРПРОТИВОВИРУСНЫЕ СРЕДСТВА /ХИМЛЕКАРСТВ ХИМИЧЕСКАЯ СТАБИЛЬНОСТЬИНГИБИТОРЫ ПРОТЕАЗЫ NS3/NS4АИНГИБИТОРЫ БЕЛКА NS5AИНГИБИТОРЫ NS5B ПОЛИМЕРАЗЫДан обзор химической структуры и её связи с ...
Жерносек, А. К., Лагодич, А. С.   +1 more
core  

Daclatasvir.

Australian prescriber, 2016
openaire   +3 more sources

Short-Term Clinical and Immunologic Outcomes Conditional on SVR12 in Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Treated With Direct-Acting Antivirals: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Boonpheng B, Ungprasert P.
europepmc   +1 more source

Biochemical and Demographic Factors Affecting Antiviral Treatment Failure in Hepatitis C Patients with Persistent Virologic Response Issues

Pakistan Journal of Medical Research
Background: Worldwide, Hepatitis C virus (HCV) infection is a major public health concern. Twelve weeks following treatment completion, the persistent virologic response is known as SVR.
Sundus Bukhari, Mutayyaba Majeed, Maria Liaqat, Sana Shakeel, Maria Muddassir, Faheem Hadi, Tahir Maqbool   +6 more
doaj  

Economic evaluations of Glecaprevir/Pibrentasvir and Grazoprevir/Elbasvir for the treatment of hepatitis C: a systematic review. [PDF]

Cost Eff Resour Alloc
Jafari M, Mehdizadeh P, Teymourzadeh E, Salesi M, Keshavarz K, Abyazi MA, Heiat M, Alavian SM.   +7 more
europepmc   +1 more source

A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran. [PDF]

Cost Eff Resour Alloc
Jafari M, Mehdizadeh P, Keshavarz K, Teymourzadeh E, Abyazi MA, Alavian SM, Pouria A.   +6 more
europepmc   +1 more source

Stevens-Johnson syndrome associated with daclatasvir and sofosbuvir co-therapy in hepatitis C treatment: a rare case report. [PDF]

Ann Med Surg (Lond)
Sajjad W, Rehman UU, Inam A, Alam I, Ghafoor S, Razzaq HD, Khwajakhail T, Gillani SHMUD, Razzaq H, Qamar I, Ali R, Ullah Z.   +11 more
europepmc   +1 more source